Article Text

Download PDFPDF

4CPS-097 Comparative effectiveness of risankizumab and secukinumab in moderate to serious psoriasis
  1. E Tejedor1,
  2. M Rodriguez Goicoechea2,
  3. D Rubio3,
  4. S Cano4
  1. 1Barcelona Clinic Hospital, Pharmacy, Barcelona, Spain
  2. 2Jaen General Hospital, Pharmacy, Jaen, Spain
  3. 3Poniente Hospital, Pharmacy, Almeria, Spain
  4. 4Virgen De Las Nieves Hospital, Pharmacy, Granada, Spain


Background and Importance In 2015, secukinumab emerged as the first anti-IL17 in psoriasis, characterised by a rapid onset of action. In 2017, the development of drugs with a new, different target of action, anti-IL23, began. The wide range of drugs and mechanisms of action makes the choice of treatment for patients with moderate to severe psoriasis increasingly complex.

Aim and Objectives Evaluation of effectiveness through indirect comparisons between risankizumab (anti-IL23) and secukinumab (anti-IL17).

Material and Methods Multicentre, observational, retrospective study to indirectly compare patients on risankizumab (RIS) and secukinumab (SEC) between June 2021 and June 2022. The anthropometric data were age, sex and previous biological treatments. comparative effectiveness was measured by the medians of the following variables: body surface area affected (BAS) scale, psoriasis area severity index (PASI), physician global assessment (PGA) at baseline, 12, 24 and 48 weeks after treatment. Safety was assessed with adverse event (EA) and the DLQI quality questionnaire were recorded. The main tools used: SAP© for the clinical history, Modulab© for laboratory values and Excel© for anonymised data recording. The information was collected according to data minimisation policy, article 5.1 of data protection.

Results A total of 111 patients were selected (60 risankizumab/50 secukinumab). The median age was 51.1 (risankizumab) and 39.8 (secukinumab). Of the patients, 63.3% were male. The main biologic treatments previously used were: Etanercept (31) > Adalimumab (23). Regarding efficacy: at baseline median BSA 11.9 vs 11.4 and PASI 8.3 vs 8.6 (SEC vs RIS), at 12 weeks BSA 1.6 vs 2.3 and PASI 1.5 vs 1.8 (SEC vs RIS), at 24 weeks BSA 1.5 vs 0.7 PASI 0.6 vs 0.7 (SEC vs RIS), and at 48 weeks BSA 1.63 vs 0.7 and PASI 0.5 vs 0.9. The main adverse events were headache and mild injection site reaction for both drugs.

Conclusion and Relevance Based on data from comparative studies, there is no significant difference between the effectiveness of risankizumab and secukinumab. More studies are needed to define the gold-standard drug.

References and/or Acknowledgements Risankizumab data sheet.

Secukinumab data sheet

Conflict of Interest No conflict of interest

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.